NLRP3 and colitis: Escherichia‐Shigella, a pathogenic bacterium frequently associated with inflammatory diseases such as colitis, has been shown to activate the NLRP3 inflammasome.[58] Thus, the inhibitory effect of HNVs on Escherichia‐Shigella, along with their ability to enhance the growth of beneficial bacteria such as Eubacterium and Turicibacter, likely plays a pivotal role in mitigating colonic inflammation and provides insight into the underlying therapeutic mechanisms of HNVs in IBDs.